E&CELL Signs CDMO Contract for Gene-Engineered Stem Cell Therapy

Advanced biopharmaceutical CDMO (Contract Development and Manufacturing Organization) and new drug development specialist company E&CELL announced that it has signed a CDMO contract worth approximately 800 million KRW with domestic advanced biopharmaceutical developer CELLeBRAIN.

The contract is valued at about 800 million KRW and the contract period lasts until March 3 of next year. The main details of the contract are not disclosed due to a confidentiality agreement between the two companies.

E&CELL is the leading company in the domestic CGT (Cell and Gene Therapy) CDMO sector in terms of sales and market share. It holds an outstanding track record in the CGT field. Additionally, E&CELL uniquely operates a global-level GMP (Good Manufacturing Practice) facility capable of simultaneously producing cells and viruses, providing one-stop services and differentiated production and quality control systems to offer optimal CDMO solutions to its clients.

CELLeBRAIN is developing gene stem cell therapies by incorporating functional genes into stem cells targeting brain diseases such as brain tumors and strokes. The company possesses innovative platform technologies necessary for developing high-efficiency, high-purity therapeutics, including gene introduction and analysis technologies. In 2018, CELLeBRAIN successfully completed investigator-led clinical trials on recurrent glioblastoma patients at CHA Hospital using gene stem cell therapies produced under contract manufacturing.

Jang Jong-wook, CEO of E&CELL, stated, "E&CELL continuously provides the best services to clients through optimized processes and quality control to meet the growing domestic and international CDMO demand. Through this contract, based on E&CELL’s core CDMO technology GMP platform, we will produce CELLeBRAIN’s gene-introduced Master Cell Bank (MCB) stem cell therapies and strive together with our client to apply them to advanced regenerative clinical research and treatments."

Seo Hae-young, CEO of CELLeBRAIN, said, "We have high confidence in E&CELL’s specialized manufacturing processes and excellent quality control capabilities for gene cell therapies, which led to this contract. We will endeavor to demonstrate the innovative therapeutic potential by advancing the therapies produced through this contract into late-stage clinical trials domestically and internationally."

Meanwhile, E&CELL is expanding collaborations with domestic and international advanced pharmaceutical developers, having signed CMO contracts with global major pharmaceutical companies such as Novartis and Janssen, including a contract with a global large pharmaceutical company last December.

This content was produced with the assistance of AI translation services.